This article only represents the author's own views.
Venus Medtech (Hangzhou) Inc. (2500.HK) is desperately trying to cure its corporate ailments, after first uncovering governance issues nearly a year ago. But the Hong Kong Stock Exchange isn’t satisfied that the transcatheter device maker is healthy enough just yet to resume trading.
Last week, Venus Medtech disclosed that the stock exchange has laid out five conditions the company must meet before its shares can trade again, following its disclosure last May that it failed to properly disclose loans made by the company to its chairman and general manager.
您已閱讀10%（613字），剩余90%（5363字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。